116 related articles for article (PubMed ID: 34219057)
1. [CAPRA score vs minimal residual disease as predictors of biochemical recurrence after radical prostatectomy.].
Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Arch Esp Urol; 2021 Jul; 74(6):554-563. PubMed ID: 34219057
[TBL] [Abstract][Full Text] [Related]
2. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
[TBL] [Abstract][Full Text] [Related]
3. The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Ecancermedicalscience; 2020; 14():1063. PubMed ID: 32728379
[TBL] [Abstract][Full Text] [Related]
4. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
[TBL] [Abstract][Full Text] [Related]
5. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
[TBL] [Abstract][Full Text] [Related]
6. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
[TBL] [Abstract][Full Text] [Related]
7. Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer.
Murray NP; Aedo S; Fuentealba C; Jacob O; Reyes E; Novoa C; Orellana S; Orellana N
Urol Oncol; 2016 Oct; 34(10):430.e17-25. PubMed ID: 27381896
[TBL] [Abstract][Full Text] [Related]
8. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
[TBL] [Abstract][Full Text] [Related]
9. The CAPRA-S Score and Immune Dysfunction as a Guide to Outcome in Men Treated with Prostatectomy Radical as Mono-Therapy for Prostate Cancer.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
Arch Esp Urol; 2022 Aug; 75(6):507-516. PubMed ID: 36138499
[TBL] [Abstract][Full Text] [Related]
10. Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
Murray NP; Aedo S; Reyes E; Orellana N; Fuentealba C; Jacob O
BJU Int; 2016 Oct; 118(4):556-62. PubMed ID: 26507242
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of biochemical recurrence-free survival after radical prostatectomy by cancer of the prostate risk assessment post-surgical (CAPRA-S) score.
Aktas BK; Ozden C; Bulut S; Tagci S; Erbay G; Gokkaya CS; Baykam MM; Memis A
Asian Pac J Cancer Prev; 2015; 16(6):2527-30. PubMed ID: 25824791
[TBL] [Abstract][Full Text] [Related]
12. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
13. External validation of the CAPRA-S score to predict biochemical recurrence, metastasis and mortality after radical prostatectomy in a European cohort.
Tilki D; Mandel P; Schlomm T; Chun FK; Tennstedt P; Pehrke D; Haese A; Huland H; Graefen M; Salomon G
J Urol; 2015 Jun; 193(6):1970-5. PubMed ID: 25498570
[TBL] [Abstract][Full Text] [Related]
14. Australian validation of the Cancer of the Prostate Risk Assessment Post-Surgical score to predict biochemical recurrence after radical prostatectomy.
Beckmann K; O'Callaghan M; Vincent A; Roder D; Millar J; Evans S; McNeil J; Moretti K
ANZ J Surg; 2018 Mar; 88(3):E183-E188. PubMed ID: 28471003
[TBL] [Abstract][Full Text] [Related]
15. Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
Asian Pac J Cancer Prev; 2018 Jan; 19(1):229-236. PubMed ID: 29374406
[TBL] [Abstract][Full Text] [Related]
16. The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy.
Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Turk J Urol; 2020 Sep; 46(5):360-366. PubMed ID: 32707032
[TBL] [Abstract][Full Text] [Related]
17. Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2497-2505. PubMed ID: 35901359
[TBL] [Abstract][Full Text] [Related]
18. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of CAPRA-S Score for Predicting Long-Term Biochemical Progression After Radical Prostatectomy.
Hernández Hernández C; Kim Lee D; Sanchez Pérez M; Escobar SH
Clin Genitourin Cancer; 2019 Jun; 17(3):e645-e649. PubMed ID: 31097389
[TBL] [Abstract][Full Text] [Related]
20. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis.
Cooperberg MR; Broering JM; Carroll PR
J Natl Cancer Inst; 2009 Jun; 101(12):878-87. PubMed ID: 19509351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]